» Articles » PMID: 11435245

Disproportionate Distribution of Burkholderia Cepacia Complex Species and Transmissibility Markers in Cystic Fibrosis

Overview
Specialty Critical Care
Date 2001 Jul 4
PMID 11435245
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

Several distinct species (genomovars) comprise bacteria previously identified merely as Burkholderia cepacia. Understanding how these species, collectively referred to as the B. cepacia complex, differ in their epidemiology and pathogenic potential in cystic fibrosis (CF) is important in efforts to refine management strategies. B. cepacia isolates recovered from 606 CF patients receiving care at 132 treatment centers in 105 cities in the United States were assessed to determine species within the B. cepacia complex and examined for the presence of putative transmissibility markers (B. cepacia epidemic strain marker [BCESM] and cable pilin subunit gene [cblA]). Fifty percent of patients were infected with B. cepacia complex genomovar III, 38% with B. multivorans (formerly genomovar II), and 5% with B. vietnamiensis (formerly genomovar V); fewer than 5% of patients were infected with either genomovar I, B. stabilis (formerly genomovar IV), genomovar VI, or genomovar VII. BCESM was found in 46% of genomovar III isolates and not in any other species. Only one isolate, from a patient infected with the ET12 epidemic lineage, contained the complete cblA pilin subunit gene. Our data indicate a differential capacity for human infection among the phylogenetically closely related species of the B. cepacia complex. The low frequency of BCESM and cblA suggests that they are not sufficient markers of B. cepacia virulence or transmissibility.

Citing Articles

Racial inequities and rare variants: Impact on cystic fibrosis diagnosis and treatment.

Wu M, Davis J, Zhao C, Daley T, Oliver K J Clin Transl Endocrinol. 2024; 36:100344.

PMID: 38765466 PMC: 11099334. DOI: 10.1016/j.jcte.2024.100344.


Harnessing the Diversity of spp. Prophages for Therapeutic Potential.

Nordstrom H, Griffith M, Rangachar Srinivasa V, Wallace N, Li A, Cooper V Cells. 2024; 13(5.

PMID: 38474392 PMC: 10931425. DOI: 10.3390/cells13050428.


Harnessing the diversity of spp. prophages for therapeutic potential.

Nordstrom H, Griffith M, Rangachar Srinivasa V, Wallace N, Li A, Cooper V bioRxiv. 2024; .

PMID: 38328162 PMC: 10849711. DOI: 10.1101/2024.01.24.577087.


Brazilian guidelines for the pharmacological treatment of the pulmonary symptoms of cystic fibrosis. Official document of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association).

Athanazio R, Tanni S, Ferreira J, Dalcin P, Fuccio M, Esposito C J Bras Pneumol. 2023; 49(2):e20230040.

PMID: 37194817 PMC: 10171269. DOI: 10.36416/1806-3756/e20230040.


Metabolomic profiling of Burkholderia cenocepacia in synthetic cystic fibrosis sputum medium reveals nutrient environment-specific production of virulence factors.

Jaiyesimi O, McAvoy A, Fogg D, Garg N Sci Rep. 2021; 11(1):21419.

PMID: 34725378 PMC: 8560942. DOI: 10.1038/s41598-021-00421-4.